HO-1 downregulation favors BRAFV600 melanoma cell death induced by Vemurafenib/PLX4032 and increases NK recognition

Anna L. Furfaro, Selene Ottonello, Giulia Loi, Irene Cossu, Sabrina Piras, Francesco Spagnolo, Paola Queirolo, Umberto M. Marinari, Lorenzo Moretta, Maria A. Pronzato, Maria C. Mingari, Gabriella Pietra, Mariapaola Nitti

Research output: Contribution to journalArticle

Abstract

Heme oxygenase 1 (HO-1) plays a pivotal role in preventing cell damage. Indeed, through the antioxidant, antiapoptotic and anti-inflammatory properties of its metabolic products, it favors cell adaptation against different stressors. However, HO-1 induction has also been related to the gain of resistance to therapy in different types of cancers and its involvement in cancer immune-escape has been hypothesized. We have investigated the role of HO-1 expression in Vemurafenib-treated BRAFV600 melanoma cells in modulating their susceptibility to NK cell-mediated recognition. Different cell lines, isolated in house from melanoma patients, have been exposed to 1–10 μM PLX4032, which efficiently reduced ERK phosphorylation. In three lines, Vemurafenib was able to induce only a limited decrease in cell viability, while HO-1 expression was upregulated. HO-1 silencing/inhibition was able to induce a further significant reduction of Vemurafenib-treated melanoma viability. Moreover, while NK cell degranulation and killing activity were decreased upon interaction with melanoma exposed to Vemurafenib, HO-1 silencing was able to completely restore NK cell ability to degranulate and kill. Furthermore, melanoma cell treatment with Vemurafenib downregulated the expression of ligands of NKp30 and NKG2D activating receptors, and HO-1 silencing/inhibition was able to restore their expression. Our results indicate that HO-1 downregulation can both improve the efficacy of Vemurafenib on melanoma cells and favor melanoma susceptibility to NK cell-mediated recognition and killing.

Original languageEnglish
JournalInternational Journal of Cancer
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Heme Oxygenase-1
Melanoma
Cell Death
Down-Regulation
Natural Killer Cells
NK Cell Lectin-Like Receptor Subfamily K
Cell Degranulation
PLX4032
Neoplasms
Cell Survival
Anti-Inflammatory Agents
Antioxidants
Phosphorylation
Ligands
Cell Line
Therapeutics

Keywords

  • HO-1
  • melanoma
  • NK and/or NKT cells
  • response and/or resistance to therapy
  • target therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

HO-1 downregulation favors BRAFV600 melanoma cell death induced by Vemurafenib/PLX4032 and increases NK recognition. / Furfaro, Anna L.; Ottonello, Selene; Loi, Giulia; Cossu, Irene; Piras, Sabrina; Spagnolo, Francesco; Queirolo, Paola; Marinari, Umberto M.; Moretta, Lorenzo; Pronzato, Maria A.; Mingari, Maria C.; Pietra, Gabriella; Nitti, Mariapaola.

In: International Journal of Cancer, 01.01.2019.

Research output: Contribution to journalArticle

Furfaro, Anna L. ; Ottonello, Selene ; Loi, Giulia ; Cossu, Irene ; Piras, Sabrina ; Spagnolo, Francesco ; Queirolo, Paola ; Marinari, Umberto M. ; Moretta, Lorenzo ; Pronzato, Maria A. ; Mingari, Maria C. ; Pietra, Gabriella ; Nitti, Mariapaola. / HO-1 downregulation favors BRAFV600 melanoma cell death induced by Vemurafenib/PLX4032 and increases NK recognition. In: International Journal of Cancer. 2019.
@article{5bb3fa5a99a24170be8a2d11c30eb10c,
title = "HO-1 downregulation favors BRAFV600 melanoma cell death induced by Vemurafenib/PLX4032 and increases NK recognition",
abstract = "Heme oxygenase 1 (HO-1) plays a pivotal role in preventing cell damage. Indeed, through the antioxidant, antiapoptotic and anti-inflammatory properties of its metabolic products, it favors cell adaptation against different stressors. However, HO-1 induction has also been related to the gain of resistance to therapy in different types of cancers and its involvement in cancer immune-escape has been hypothesized. We have investigated the role of HO-1 expression in Vemurafenib-treated BRAFV600 melanoma cells in modulating their susceptibility to NK cell-mediated recognition. Different cell lines, isolated in house from melanoma patients, have been exposed to 1–10 μM PLX4032, which efficiently reduced ERK phosphorylation. In three lines, Vemurafenib was able to induce only a limited decrease in cell viability, while HO-1 expression was upregulated. HO-1 silencing/inhibition was able to induce a further significant reduction of Vemurafenib-treated melanoma viability. Moreover, while NK cell degranulation and killing activity were decreased upon interaction with melanoma exposed to Vemurafenib, HO-1 silencing was able to completely restore NK cell ability to degranulate and kill. Furthermore, melanoma cell treatment with Vemurafenib downregulated the expression of ligands of NKp30 and NKG2D activating receptors, and HO-1 silencing/inhibition was able to restore their expression. Our results indicate that HO-1 downregulation can both improve the efficacy of Vemurafenib on melanoma cells and favor melanoma susceptibility to NK cell-mediated recognition and killing.",
keywords = "HO-1, melanoma, NK and/or NKT cells, response and/or resistance to therapy, target therapy",
author = "Furfaro, {Anna L.} and Selene Ottonello and Giulia Loi and Irene Cossu and Sabrina Piras and Francesco Spagnolo and Paola Queirolo and Marinari, {Umberto M.} and Lorenzo Moretta and Pronzato, {Maria A.} and Mingari, {Maria C.} and Gabriella Pietra and Mariapaola Nitti",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/ijc.32611",
language = "English",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - HO-1 downregulation favors BRAFV600 melanoma cell death induced by Vemurafenib/PLX4032 and increases NK recognition

AU - Furfaro, Anna L.

AU - Ottonello, Selene

AU - Loi, Giulia

AU - Cossu, Irene

AU - Piras, Sabrina

AU - Spagnolo, Francesco

AU - Queirolo, Paola

AU - Marinari, Umberto M.

AU - Moretta, Lorenzo

AU - Pronzato, Maria A.

AU - Mingari, Maria C.

AU - Pietra, Gabriella

AU - Nitti, Mariapaola

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Heme oxygenase 1 (HO-1) plays a pivotal role in preventing cell damage. Indeed, through the antioxidant, antiapoptotic and anti-inflammatory properties of its metabolic products, it favors cell adaptation against different stressors. However, HO-1 induction has also been related to the gain of resistance to therapy in different types of cancers and its involvement in cancer immune-escape has been hypothesized. We have investigated the role of HO-1 expression in Vemurafenib-treated BRAFV600 melanoma cells in modulating their susceptibility to NK cell-mediated recognition. Different cell lines, isolated in house from melanoma patients, have been exposed to 1–10 μM PLX4032, which efficiently reduced ERK phosphorylation. In three lines, Vemurafenib was able to induce only a limited decrease in cell viability, while HO-1 expression was upregulated. HO-1 silencing/inhibition was able to induce a further significant reduction of Vemurafenib-treated melanoma viability. Moreover, while NK cell degranulation and killing activity were decreased upon interaction with melanoma exposed to Vemurafenib, HO-1 silencing was able to completely restore NK cell ability to degranulate and kill. Furthermore, melanoma cell treatment with Vemurafenib downregulated the expression of ligands of NKp30 and NKG2D activating receptors, and HO-1 silencing/inhibition was able to restore their expression. Our results indicate that HO-1 downregulation can both improve the efficacy of Vemurafenib on melanoma cells and favor melanoma susceptibility to NK cell-mediated recognition and killing.

AB - Heme oxygenase 1 (HO-1) plays a pivotal role in preventing cell damage. Indeed, through the antioxidant, antiapoptotic and anti-inflammatory properties of its metabolic products, it favors cell adaptation against different stressors. However, HO-1 induction has also been related to the gain of resistance to therapy in different types of cancers and its involvement in cancer immune-escape has been hypothesized. We have investigated the role of HO-1 expression in Vemurafenib-treated BRAFV600 melanoma cells in modulating their susceptibility to NK cell-mediated recognition. Different cell lines, isolated in house from melanoma patients, have been exposed to 1–10 μM PLX4032, which efficiently reduced ERK phosphorylation. In three lines, Vemurafenib was able to induce only a limited decrease in cell viability, while HO-1 expression was upregulated. HO-1 silencing/inhibition was able to induce a further significant reduction of Vemurafenib-treated melanoma viability. Moreover, while NK cell degranulation and killing activity were decreased upon interaction with melanoma exposed to Vemurafenib, HO-1 silencing was able to completely restore NK cell ability to degranulate and kill. Furthermore, melanoma cell treatment with Vemurafenib downregulated the expression of ligands of NKp30 and NKG2D activating receptors, and HO-1 silencing/inhibition was able to restore their expression. Our results indicate that HO-1 downregulation can both improve the efficacy of Vemurafenib on melanoma cells and favor melanoma susceptibility to NK cell-mediated recognition and killing.

KW - HO-1

KW - melanoma

KW - NK and/or NKT cells

KW - response and/or resistance to therapy

KW - target therapy

UR - http://www.scopus.com/inward/record.url?scp=85071561491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071561491&partnerID=8YFLogxK

U2 - 10.1002/ijc.32611

DO - 10.1002/ijc.32611

M3 - Article

C2 - 31376303

AN - SCOPUS:85071561491

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

ER -